Switching Maintenance Infliximab Therapy to Biosimilar-Infliximab does Not Lead to Significant Changes in Health-Related Quality of Life and Clinical Outcomes in Inflammatory Bowel Disease Patients
Abstract
Authors
S Huoponen A Eberl P Räsänen RP Roine T Sipponen P Arkkila M Blom